Thrombopoietin receptor activation by myeloproliferative neoplasm associated calreticulin mutants
- PMID: 26668133
- DOI: 10.1182/blood-2015-11-681932
Thrombopoietin receptor activation by myeloproliferative neoplasm associated calreticulin mutants
Abstract
Mutations in the calreticulin gene (CALR) represented by deletions and insertions in exon 9 inducing a -1/+2 frameshift are associated with a significant fraction of myeloproliferative neoplasms (MPNs). The mechanisms by which CALR mutants induce MPN are unknown. Here, we show by transcriptional, proliferation, biochemical, and primary cell assays that the pathogenic CALR mutants specifically activate the thrombopoietin receptor (TpoR/MPL). No activation is detected with a battery of type I and II cytokine receptors, except granulocyte colony-stimulating factor receptor, which supported only transient and weak activation. CALR mutants induce ligand-independent activation of JAK2/STAT/phosphatydylinositol-3'-kinase (PI3-K) and mitogen-activated protein (MAP) kinase pathways via TpoR, and autonomous growth in Ba/F3 cells. In these transformed cells, no synergy is observed between JAK2 and PI3-K inhibitors in inhibiting cytokine-independent proliferation, thus showing a major difference from JAK2V617F cells where such synergy is strong. TpoR activation was dependent on its extracellular domain and its N-glycosylation, especially at N117. The glycan binding site and the novel C-terminal tail of the mutant CALR proteins were required for TpoR activation. A soluble form of TpoR was able to prevent activation of full-length TpoR provided that it was N-glycosylated. By confocal microscopy and subcellular fractionation, CALR mutants exhibit different intracellular localization from that of wild-type CALR. Finally, knocking down either MPL/TpoR or JAK2 in megakaryocytic progenitors from patients carrying CALR mutations inhibited cytokine-independent megakaryocytic colony formation. Taken together, our study provides a novel signaling paradigm, whereby a mutated chaperone constitutively activates cytokine receptor signaling.
© 2016 by The American Society of Hematology.
Comment in
-
Mutant calreticulin: when a chaperone becomes intrusive.Blood. 2016 Mar 10;127(10):1219-21. doi: 10.1182/blood-2016-01-694182. Blood. 2016. PMID: 26965919
Similar articles
-
Activation of the thrombopoietin receptor by mutant calreticulin in CALR-mutant myeloproliferative neoplasms.Blood. 2016 Mar 10;127(10):1307-16. doi: 10.1182/blood-2015-09-671172. Epub 2016 Jan 27. Blood. 2016. PMID: 26817954
-
Mutant calreticulin in myeloproliferative neoplasms.Blood. 2019 Dec 19;134(25):2242-2248. doi: 10.1182/blood.2019000622. Blood. 2019. PMID: 31562135 Free PMC article.
-
Mechanism underlying the development of myeloproliferative neoplasms through mutant calreticulin.Cancer Sci. 2020 Aug;111(8):2682-2688. doi: 10.1111/cas.14503. Epub 2020 Jun 27. Cancer Sci. 2020. PMID: 32462673 Free PMC article. Review.
-
Defining the requirements for the pathogenic interaction between mutant calreticulin and MPL in MPN.Blood. 2018 Feb 15;131(7):782-786. doi: 10.1182/blood-2017-08-800896. Epub 2017 Dec 29. Blood. 2018. PMID: 29288169 Free PMC article.
-
Unfolding the Role of Calreticulin in Myeloproliferative Neoplasm Pathogenesis.Clin Cancer Res. 2019 May 15;25(10):2956-2962. doi: 10.1158/1078-0432.CCR-18-3777. Epub 2019 Jan 17. Clin Cancer Res. 2019. PMID: 30655313 Free PMC article. Review.
Cited by
-
When Glycosylation Meets Blood Cells: A Glance of the Aberrant Glycosylation in Hematological Malignancies.Rev Physiol Biochem Pharmacol. 2021;180:85-117. doi: 10.1007/112_2021_60. Rev Physiol Biochem Pharmacol. 2021. PMID: 34031738 Review.
-
Ruxolitinib dose management as a key to long-term treatment success.Int J Hematol. 2016 Oct;104(4):420-9. doi: 10.1007/s12185-016-2084-1. Epub 2016 Aug 27. Int J Hematol. 2016. PMID: 27567907 Review.
-
Defective interaction of mutant calreticulin and SOCE in megakaryocytes from patients with myeloproliferative neoplasms.Blood. 2020 Jan 9;135(2):133-144. doi: 10.1182/blood.2019001103. Blood. 2020. PMID: 31697806 Free PMC article.
-
Platelet function studies in myeloproliferative neoplasms patients with Calreticulin or JAK2 V617F mutation.Res Pract Thromb Haemost. 2023 Jan 31;7(2):100060. doi: 10.1016/j.rpth.2023.100060. eCollection 2023 Feb. Res Pract Thromb Haemost. 2023. PMID: 36908768 Free PMC article.
-
Molecular Pathogenesis of Myeloproliferative Neoplasms: From Molecular Landscape to Therapeutic Implications.Int J Mol Sci. 2022 Apr 20;23(9):4573. doi: 10.3390/ijms23094573. Int J Mol Sci. 2022. PMID: 35562964 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials
Miscellaneous